Light Mode
$127.99 ↑ +2.89 (+2.31%) Trading Up from the previous close of $125.10
-3.54 (-2.75%) / 6M
Momentum, market sentiment, and recent alerts
PVLA reads very good: price sits above one of the two key moving averages, the 12-month move is +77.6%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.